Cancer Research and Treatment

Case Report

Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide: Aery Choi, Young Kyung Kang, Sewon Lim, Dong Ho Kim, Jung Sub Lim, Jun Ah Lee; Cancer Res Treat. 2016;48(4):1443-1447. Published online March 30, 2016; DOI: https://doi.org/10.4143/crt.2016.096

Hepatic sinusoidal obstruction syndrome (SOS) is a life-threatening syndrome that generally occurs as a complication after hematopoietic stem cell transplantation or, less commonly, after conventional chemotherapy. Regarding SOS in rhabdomyosarcoma patients who received conventional chemotherapy, the doses of chemotherapeutic agents are associated with the development of SOS. Several cases of SOS in rhabdomyosarcoma patients after receiving chemotherapy with escalated doses of cyclophosphamide have been reported. Here, we report on a 9-year-old female with rhabdomyosarcoma who developed severe SOS after receiving chemotherapy consisting of vincristine, actinomycin-D, and a moderate dose of cyclophosphamide. She was treated successfully with defibrotide without sequelae to the liver.

Citations

Citations to this article as recorded by

Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives
Zaoqin Yu, Wei Li, Cheng Tian, Yan Cao, Chengliang Zhang
Archives of Toxicology.2024;[Epub] CrossRef
Treatment of Sinusoidal Obstruction Syndrome With Defibrotide in Pediatric Cancer Patients Following Nontransplant-associated Chemotherapy: A Case Report and Review of the Literature
Marc R. Lawrence, Mylène Bassal, Raveena Ramphal, Donna L. Johnston
Journal of Pediatric Hematology/Oncology.2022; 44(3): e788. CrossRef
Indispensable role of microbes in anticancer drugs and discovery trends
Ridam Kapoor, Anamika Saini, Deepika Sharma
Applied Microbiology and Biotechnology.2022; 106(13-16): 4885. CrossRef
Caspase inhibitor z-VAD-FMK increases the survival of hair cells after Actinomycin-D-induced damage in vitro
Huimin Chang, Fei Sun, Keyong Tian, Weilong Wang, Ke Zhou, Dingjun Zha, Jianhua Qiu
Neuroscience Letters.2020; 732: 135089. CrossRef
Adjuvant recombinant thrombomodulin therapy for hepatopathy induced by vincristine, actinomycin D, and cyclophosphamide in pediatric rhabdomyosarcoma: A case report
Tetsuko Kobayashi, Maiko Noguchi, Hideki Nakayama, Reiji Fukano, Shouichi Ohga
Molecular and Clinical Oncology.2019;[Epub] CrossRef
“Pre‐emptive strike”—the case for early treatment of hepatic sinusoidal obstruction syndrome with defibrotide
Revathi Rajagopal, Marianne B. Phillips, Nicholas G. Gottardo
Pediatric Blood & Cancer.2018;[Epub] CrossRef
Cyclophosphamide/dactinomycin/vincristine

Reactions Weekly.2017; 1637(1): 75. CrossRef

10,609 View
207 Download
7 Web of Science
7 Crossref

Original Articles

Immunogenicity of Influenza Vaccine in Colorectal Cancer Patients: Dong Ho Kim, Yun Yong Lee, Ui Sup Shin, Sun Mi Moon; Cancer Res Treat. 2013;45(4):303-312. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.303

Abstract PDF PubReader ePub

PURPOSE
Although influenza is regarded as a major cause of morbidity and mortality in immunocompromised patients, vaccine coverage remains poor. We evaluated the immunogenicity of influenza vaccines in colorectal cancer patients.
MATERIALS AND METHODS
In this study, 40 colorectal cancer patients who received an influenza vaccine at the Korea Cancer Center Hospital during the 2009-2010 and 2010-2011 influenza seasons were analyzed. The blood samples were collected at prevaccination and 30 days post vaccination, and antibody titers were measured using the hemagglutination-inhibition tests.
RESULTS
In the 2009-2011 season, the seroprotection rate for H1N1 (94.7%) was significantly higher than that for H3N2 (42.1%) and B (47.3%). The seroconversion rate was 52.6%, 26.3%, and 36.8% for H1N1, H3N2, and B, respectively. Fold increase of geometric mean titer (MFI) was 3.86, 1.49, and 3.33 for H1N1, H3N2, and B, respectively. In the 2010-2011 season, the seroprotection rate for H1N1 (57.1%) was significantly higher than that for H3N2 (52.4%) and B (38.1%). The seroconversion rate was 52.4%, 47.6% and 33.3% for H1N1, H3N2, and B, respectively. MFI was 12.29, 3.62 and 4.27 for H1N1, H3N2, and B, respectively.
CONCLUSION
Our study cohort showed an acceptable immune response to an influenza vaccine without significant adverse effects, supporting the recommendation for annual influenza vaccination in colorectal cancer patients.

Citations

Citations to this article as recorded by

Therapeutic vaccines for colorectal cancer: The progress and future prospect
Mina Shahnazari, Pouria Samadi, Mona Pourjafar, Akram Jalali
International Immunopharmacology.2020; 88: 106944. CrossRef
Vaccines for colorectal cancer: an update
Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh
Journal of Cellular Biochemistry.2019; 120(6): 8815. CrossRef
Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season
Maria Ganczak, Paulina Dubiel, Marzena Drozd-Dąbrowska, Ewelina Hallmann-Szelińska, Karol Szymański, Lidia B. Brydak
International Journal of Environmental Research and Public Health.2019; 16(22): 4489. CrossRef
Immunogenicity of Influenza Vaccination in Patients With Cancer
Saiama N. Waqar, Leigh Boehmer, Daniel Morgensztern, Andrea Wang-Gillam, Steven Sorscher, Steven Lawrence, Feng Gao, Kalin Guebert, Kristina Williams, Ramaswamy Govindan
American Journal of Clinical Oncology.2018; 41(3): 248. CrossRef
Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy
Kei Nakashima, Masahiro Aoshima, Satoko Ohfuji, Kanzo Suzuki, Masahiro Katsurada, Naoko Katsurada, Masafumi Misawa, Yoshihito Otsuka, Kyoko Kondo, Yoshio Hirota
Human Vaccines & Immunotherapeutics.2017; 13(3): 543. CrossRef
Influenza vaccination in adult patients with solid tumours treated with chemotherapy
Albert Vollaard, Imke Schreuder, Lizzy Slok-Raijmakers, Wim Opstelten, Guus Rimmelzwaan, Hans Gelderblom
European Journal of Cancer.2017; 76: 134. CrossRef
Vaccination in Patients with Primary Immune Deficiency, Secondary Immune Deficiency and Autoimmunity with Immune Regulatory Abnormalities
Martha M Eibl, Hermann M Wolf
Immunotherapy.2015; 7(12): 1273. CrossRef

44,736 View
59 Download
7 Crossref

Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?: Jun Ah Lee, Yunmi Ko, Dong Ho Kim, Jung Sub Lim, Chang-Bae Kong, Wan Hyeong Cho, Dae-Geun Jeon, Soo-Yong Lee, Jae-Soo Koh; Cancer Res Treat. 2012;44(3):202-209. Published online September 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.3.202

Abstract PDF PubReader ePub

PURPOSE
Features of epidermal growth factor receptor (EGFR) expression in osteosarcoma and in vitro efficacies of EGFR inhibitors against osteosarcoma cells were evaluated.
MATERIALS AND METHODS
Thirty biopsy samples of osteosarcoma patients were retrospectively analyzed for EGFR protein expression by immunohistochemistry. Relationships between EGFR expression and clinicopathologic characteristics and treatment outcomes were evaluated. Four osteosarcoma cell lines were analyzed for EGFR and p-EGFR expression by western blotting. Efficacies of gefitinib and BIBW2992 on osteosarcoma cells were evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Tyrosine kinase domains in exons 18 to 21 were sequenced and gene expression analyses of EGFR and PTEN were performed in four osteosarcoma cell lines.
RESULTS
EGFR protein was expressed in 27 (90%) samples (6 low, 12 intermediate, 9 high) and in three cell lines. Intermediate or high staining for EGFR was related to a tumor volume<150 mL (p<0.001) and histologic subtype other than osteoblastic type (p=0.03). However, EGFR expression was not associated with histologic response to preoperative chemotherapy or survival. Gefitinib and BIBW 2992 did not have any significant inhibitory effect on cell viabilities. DNA sequencing analysis revealed three osteosarcoma cell lines have single base changes at codon 2361 of exon 20 (G to A), without affecting translation results. Furthermore, no mutation was found to be associated with constitutive EGFR activation.
CONCLUSION
In the present study, gefitinib and BIBW2992 were not effective against osteosarcoma cells. However, as osteosarcoma cells express EGFR, further studies are necessary to explore the potential of other therapeutic agents targeting EGFR.

Citations

Citations to this article as recorded by

PD-L1, STAT3, IL6, and EGFR Immunoexpressions in High-Grade Osteosarcoma
Nayla Rahmadiani, Eviana Norahmawati, Agustina Tri Endharti, Ailen Oktaviana Hambalie, Satria Pandu Persada Isma, Raffaele Vitiello
Advances in Orthopedics.2024; 2024: 1. CrossRef
Optimizing near infrared laser irradiation and photosensitizer accumulation period for indocyanine green-mediated photodynamic therapy in breast cancer xenografts: a focus on treatment and characterization
Hasim Ozgur Tabakoglu, Tuğba Kiriş Aydoğan, Ayşenur Kiriş, Saadet Akbulut
Lasers in Medical Science.2024;[Epub] CrossRef
EGFR-targeting peptide conjugated polymer–lipid hybrid nanoparticles for delivery of salinomycin to osteosarcoma
Longhai Du, Yanlong Xu, Binxu Han, Yu Wang, Qingmin Zeng, Minghao Shao, Zuochong Yu
Journal of Cancer Research and Therapeutics.2023; 19(6): 1544. CrossRef
Epidermal growth factor signalling pathway in endochondral ossification: an evidence-based narrative review
L. Mangiavini, G. M. Peretti, B. Canciani, N. Maffulli
Annals of Medicine.2022; 54(1): 37. CrossRef
Synergistic effect of growth factor receptor-bound protein 2/epidermal growth factor receptor dual-targeting peptide inhibitor and salinomycin on osteosarcoma
Zuochong Yu, Yanlong Xu, Longhai Du, Fan Zhang, Minghao Shao, Lin Xie, Guoping Cai, Feizhou Lyu
Journal of Cancer Research and Therapeutics.2022; 18(2): 352. CrossRef
Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway
Shenglin Wang, Yunqing Wang, Zhen Huang, Hongxiang Wei, Xinwen Wang, Rongkai Shen, Wenbin Lan, Guangxian Zhong, Jianhua Lin
Acta Biochimica et Biophysica Sinica.2021; 53(12): 1670. CrossRef
Afatinib is active in osteosarcoma in osteosarcoma cell lines
Marlid Cruz-Ramos, Yessica Zamudio-Cuevas, Daniel Medina-Luna, Karina Martínez-Flores, Gabriela Martínez-Nava, Javier Fernández-Torres, Alberto López-Reyes, Flavio Solca
Journal of Cancer Research and Clinical Oncology.2020; 146(7): 1693. CrossRef
The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas
Xiaochun Wang, Reichelle X. Yeo, Philip J. Hogg, David Goldstein, Philip Crowe, Pierre J. Dilda, Jia-Lin Yang
Oncotarget.2020; 11(1): 46. CrossRef
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
Ingrid Lilienthal, Nikolas Herold
International Journal of Molecular Sciences.2020; 21(18): 6885. CrossRef
Prospects for NK Cell Therapy of Sarcoma
Mieszko Lachota, Marianna Vincenti, Magdalena Winiarska, Kjetil Boye, Radosław Zagożdżon, Karl-Johan Malmberg
Cancers.2020; 12(12): 3719. CrossRef
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment
Wei Wang, Hua-fu Zhao, Teng-fei Yao, Hao Gong
Investigational New Drugs.2019; 37(1): 175. CrossRef
The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells
Tian Wang, Dexing Wang, Lian Zhang, Ping Yang, Jing Wang, Qi Liu, Fei Yan, Feng Lin
Journal of Experimental & Clinical Cancer Research.2019;[Epub] CrossRef
Interpretation of Tongue Squamous Cell Carcinoma via Protein-Protein Interaction Network Construction and Analysis
Mona Zamanian Azodi, Mostafa Rezaei-Tavirani, Majid Rezaei-Tavirani, Vahid Mansouri, Reza Vafaee
International Journal of Cancer Management.2018;[Epub] CrossRef
EGFR is required for FOS‐dependent bone tumor development via RSK2/CREB signaling
Markus Linder, Elisabeth Glitzner, Sriram Srivatsa, Latifa Bakiri, Kazuhiko Matsuoka, Parastoo Shahrouzi, Monika Dumanic, Philipp Novoszel, Thomas Mohr, Oliver Langer, Thomas Wanek, Markus Mitterhauser, Erwin F Wagner, Maria Sibilia
EMBO Molecular Medicine.2018;[Epub] CrossRef
Prognostic significance of the expression of HER family members in primary osteosarcoma
Sheng‑Lin Wang, Guang‑Xian Zhong, Xin‑Wen Wang, Feng‑Qiang Yu, Dan‑Feng Weng, Xin‑Xing Wang, Jian‑Hua Lin
Oncology Letters.2018;[Epub] CrossRef
Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells
Fernanda B. Mantovani, Jodi A. Morrison, Anthony J. Mutsaers
BMC Veterinary Research.2016;[Epub] CrossRef
Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
Sara Westrøm, Tina B. Bønsdorff, Nasir Abbas, Øyvind S. Bruland, Thora J. Jonasdottir, Gunhild M. Mælandsmo, Roy H. Larsen, Salvatore V Pizzo
PLOS ONE.2016; 11(10): e0165382. CrossRef
Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies
Pierre J. Marie
Cellular and Molecular Life Sciences.2015; 72(7): 1347. CrossRef
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
Aude I. Ségaliny, Marta Tellez-Gabriel, Marie-Françoise Heymann, Dominique Heymann
Journal of Bone Oncology.2015; 4(1): 1. CrossRef
EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance
Florian Sevelda, Lisa Mayr, Bernd Kubista, Daniela Lötsch, Sushilla van Schoonhoven, Reinhard Windhager, Christine Pirker, Michael Micksche, Walter Berger
Journal of Experimental & Clinical Cancer Research.2015;[Epub] CrossRef
Amphiregulin enhances intercellular adhesion molecule-1 expression and promotes tumor metastasis in human osteosarcoma
Ju-Fang Liu, Ya-Ting Tsao, Chun-Han Hou
Oncotarget.2015; 6(38): 40880. CrossRef
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib
Jiani Liu, Jiangxue Wu, Ling Zhou, Changchuan Pan, Yi Zhou, Wuying Du, Jie-min Chen, Xiaofeng Zhu, Jingnan Shen, Shuai Chen, Ran-yi Liu, Wenlin Huang
Oncotarget.2015; 6(25): 21341. CrossRef
Molecular profiling of childhood cancer: Biomarkers and novel therapies
Federica Saletta, Carol Wadham, David S. Ziegler, Glenn M. Marshall, Michelle Haber, Geoffrey McCowage, Murray D. Norris, Jennifer A. Byrne
BBA Clinical.2014; 1: 59. CrossRef
ErbB Receptors as Prognostic and Therapeutic Drug Targets in Bone and Soft Tissue Sarcomas
Hongsheng Wang, Qingbo Yang, Zeze Fu, Dongqing Zuo, Yingqi Hua, Zhengdong Cai
Cancer Investigation.2014; 32(10): 533. CrossRef
Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models
Bérengère Gobin, Gatien Moriceau, Benjamin Ory, Céline Charrier, Régis Brion, Frederic Blanchard, Françoise Redini, Dominique Heymann, Gerard Roel Rutteman
PLoS ONE.2014; 9(3): e90795. CrossRef
Focal Chromosomal Copy Number Aberrations Identify CMTM8 and GPR177 as New Candidate Driver Genes in Osteosarcoma
Joeri Both, Oscar Krijgsman, Johannes Bras, Gerard R. Schaap, Frank Baas, Bauke Ylstra, Theo J. M. Hulsebos, David Loeb
PLoS ONE.2014; 9(12): e115835. CrossRef
Gefitinib and Luteolin Cause Growth Arrest of Human Prostate Cancer PC-3 Cells via Inhibition of Cyclin G-Associated Kinase and Induction of miR-630
Minami A. Sakurai, Yuki Ozaki, Daisuke Okuzaki, Yoko Naito, Towa Sasakura, Ayumi Okamoto, Hiroe Tabara, Takao Inoue, Man Hagiyama, Akihiko Ito, Norikazu Yabuta, Hiroshi Nojima, Ichiro Aoki
PLoS ONE.2014; 9(6): e100124. CrossRef
Clinical Predictive Value of Serum Angiogenic Factor in Patients with Osteosarcoma
Zhe Chen, Qi-Xin Chen, Zhao-Yang Hou, Jiong Hu, Yan-Guang Cao
Asian Pacific Journal of Cancer Prevention.2012; 13(9): 4823. CrossRef

11,595 View
79 Download
28 Crossref

Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience: Dong Hwan Kim, Seung Yeon Kim, Hyeon Jeong Lee, Bong Sup Song, Dong Ho Kim, Joong Bum Cho, Jung Sub Lim, Jun Ah Lee; Cancer Res Treat. 2011;43(3):170-175. Published online September 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.3.170

Abstract PDF PubReader ePub

PURPOSE
Response to neo-adjuvant chemotherapy is an important prognostic factor for osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT). [F-18]-fluorodeoxy-D-glucose (FDG)-positron emission tomography (PET) is a non-invasive imaging modality that predicts histologic response to chemotherapy of various malignancies; however, limited data exist about the usefulness of FDG-PET in predicting the histologic response of pediatric bone tumors to chemotherapy. We analyzed the FDG-PET imaging characteristics of pediatric bone tumors and determined the association with response to chemotherapy.
MATERIALS AND METHODS
Pediatric patients with OS (n=19) or ESFT (n=17) were evaluated for FDG-PET standard uptake values before (SUV1) and after (SUV2) chemotherapy. The relationship to the chemotherapy response was assessed by histopathology in surgically-excised tumors. A complete data set (SUV1, SUV2, and histologic response) was available in 23 patients.
RESULTS
While the mean SUV1s were not different between patients with OSs and ESFTs (9.44 vs. 6.07, p=0.24), the SUV2s were greater in the patients with OSs than ESFTs (4.55 vs. 1.66, p=0.01). The ratios of SUV2-to-SUV1 (SUV2 : SUV1) were 0.65 and 0.35 for OS and ESFT, respectively (p=0.08). All of the patients with ESFTs and 47% of the patients with OS had a favorable histologic response to chemotherapy. The SUV2 : 1 [(SUV1-SUV2)/SUV1]> or =0.5 and SUV2< or =2.5 were related to favorable histologic responses to chemotherapy; the sensitivity and specificity of SUV2 : 1 at 0.5 and SUV2 at 2.5 were 93% and 88%, and 88% and 78%, respectively.
CONCLUSION
FDG-PET can be used as a non-invasive surrogate to predict response to chemotherapy in children with bone tumors.

Citations

Citations to this article as recorded by

18F-FDG PET/CT in the Management of Osteosarcoma
Chiwoo Oh, Michael W. Bishop, Steve Y. Cho, Hyung-Jun Im, Barry L. Shulkin
Journal of Nuclear Medicine.2023; 64(6): 842. CrossRef
[18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma
Alessio Annovazzi, Virginia Ferraresi, Vincenzo Anelli, Renato Covello, Sabrina Vari, Carmine Zoccali, Roberto Biagini, Rosa Sciuto
European Radiology.2021; 31(9): 7012. CrossRef
Different 18F‐FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors
Gihan El‐Hennawy, Hosna Moustafa, Walid Omar, Naglaa Elkinaai, Ahmad Kamel, Iman Zaki, Nesma Farid, Esraa El‐Kholy
Pediatric Blood & Cancer.2020;[Epub] CrossRef
Sarcomes osseux
J.L. Albérini, P.Y. Salaün
Médecine Nucléaire.2019; 43(1): 138. CrossRef
Diagnostic Accuracy of 18F-FDG PET/CT in the Staging and Assessment of Response to Chemotherapy in Children With Ewing Sarcoma
Antonio Ruggiero, Valerio Lanni, Alberto Librizzi, Palma Maurizi, Giorgio Attinà, Stefano Mastrangelo, Alessandro Giordano, Riccardo Riccardi
Journal of Pediatric Hematology/Oncology.2018; 40(4): 277. CrossRef
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence
Andrea Angelini, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giulia Polverari, Giulia Trovarelli, Emanuela Palmerini, Stefano Ferrari, Stefano Fanti, Pietro Ruggieri
European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(10): 1712. CrossRef
PET/CT of Osteosarcoma and Ewing Sarcoma
Colleen M. Costelloe, Hubert H. Chuang, Najat C. Daw
Seminars in Roentgenology.2017; 52(4): 255. CrossRef
Qualitative and Semi-Quantitative 18-F FDG PET/CT for Osteosarcoma: A Review
Lorenzo Nardo, Michelle Zhang, Luca Facchetti, Benjamin L. Franc
Current Radiology Reports.2017;[Epub] CrossRef
Tumour hypoxia: lessons learnt from preclinical imaging
Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
Clinical and Translational Imaging.2017; 5(5): 407. CrossRef
Assessment of response to treatment in paediatric bone sarcomas by means of PET imaging
Natale Quartuccio, Byung Hyun Byun, Pierpaolo Alongi, Federico Caobelli, Chang-Bae Kong, Sang Moo Lim, Angelina Cistaro
Clinical and Translational Imaging.2016; 4(1): 41. CrossRef
Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
G. N. Machak, A. K. Morozov, A. I. Snetkov, I. N. Karpov, N. V. Kochergina, A. B. Bludov, A. D. Ryzhkov
Vestnik travmatologii i ortopedii imeni N.N. Priorova.2016; (3): 53. CrossRef
Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
G. N Machak, A. K Morozov, A. I Snetkov, I. N Karpov, N. V Kochergina, A. B Bludov, A. D Ryzhkov
N.N. Priorov Journal of Traumatology and Orthopedics.2016; 23(3): 53. CrossRef
Radiotherapy and gemcitabine–docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma
Jun Ah Lee, Eun Kyung Paik, Juhee Seo, Dong Ho Kim, Jung Sub Lim, Ji Young Yoo, Mi-Sook Kim
Japanese Journal of Clinical Oncology.2015; : hyv171. CrossRef
Tumor‐to‐background Ratio to Predict Response to Chemotherapy of Osteosarcoma Better than Standard Uptake Values
Jin‐peng He, Yun Hao, Mi Li, Jiang Wang, Feng‐jin Guo
Orthopaedic Surgery.2014; 6(2): 145. CrossRef
Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Otto C. Boerman, Winette T.A. van der Graaf
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2014; 1845(2): 266. CrossRef
FDG PET/CT of Primary Bone Tumors
Colleen M. Costelloe, Hubert H. Chuang, John E. Madewell
American Journal of Roentgenology.2014; 202(6): W521. CrossRef
Atypical growth on MRI in a case of Ewing’s sarcoma despite lower SUV on PET
Zachary Sanford, Stanford Israelsen, Rajesh Sehgal, Felix H. Cheung
Skeletal Radiology.2014; 43(6): 819. CrossRef
Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models
Carmen Campanile, Matthias J.E. Arlt, Stefanie D. Krämer, Michael Honer, Ana Gvozdenovic, Patrick Brennecke, Cindy R. Fischer, Adam A. Sabile, Adrienne Müller, Simon M. Ametamey, Walter Born, Roger Schibli, Bruno Fuchs
Journal of Nuclear Medicine.2013; 54(8): 1362. CrossRef
Promise and pitfalls of quantitative imaging in oncology clinical trials
Brenda F. Kurland, Elizabeth R. Gerstner, James M. Mountz, Lawrence H. Schwartz, Christopher W. Ryan, Michael M. Graham, John M. Buatti, Fiona M. Fennessy, Edward A. Eikman, Virendra Kumar, Kenneth M. Forster, Richard L. Wahl, Frank S. Lieberman
Magnetic Resonance Imaging.2012; 30(9): 1301. CrossRef
18F NaF PET/CT in the Assessment of Malignant Bone Disease
Camila Mosci, Andrei Iagaru
PET Clinics.2012; 7(3): 263. CrossRef
The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma
Carmelo Caldarella, Marco Salsano, Maria Antonietta Isgrò, Giorgio Treglia
International Journal of Molecular Imaging.2012; 2012: 1. CrossRef

12,480 View
71 Download
21 Crossref

Case Report

Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management: Kang Min Lee, Hee Woo Lee, Seung Yeon Kim, Hyeon Jeong Lee, Dong Hwan Kim, Joongbum Cho, Dong Ho Kim, Jung Sub Lim, Jin Kyung Lee, Jun Ah Lee; Cancer Res Treat. 2011;43(1):67-70. Published online March 31, 2011; DOI: https://doi.org/10.4143/crt.2011.43.1.67

Abstract PDF PubReader ePub

High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G2 is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.

Citations

Citations to this article as recorded by

The Role of Single Nucleotide Polymorphisms in Transporter Proteins and the Folate Metabolism Pathway in Delayed Methotrexate Excretion: A Case Report and Literature Review
Jun Wang, Yue-Tao Zhao, Meng-Jiao Sun, Feng Chen, Hong-Li Guo
Pharmacogenomics and Personalized Medicine.2022; Volume 15: 919. CrossRef
Toxicité rénale des anticancéreux
Blandine Aloy, Nicolas Janus, Corine Isnard-Bagnis, Gilbert Deray, Vincent Launay-Vacher
Néphrologie & Thérapeutique.2021; 17(7): 553. CrossRef
Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients
Wei Zhang, Qing Zhang, Ting-Ting Zheng, Jian-Cun Zhen, Xiao-Hui Niu
Chinese Medical Journal.2016; 129(21): 2530. CrossRef

8,863 View
53 Download
3 Crossref

Original Article

The Survival of Osteosarcoma Patients 10 Years Old or Younger Is Not Worse than the Survival of Older Patients: A Retrospective Analysis: Jun Ah Lee, Dong Ho Kim, Jung Sub Lim, Kyung Duk Park, Won Seok Song, Soo-Yong Lee, Dae-Geun Jeon; Cancer Res Treat. 2007;39(4):160-164. Published online December 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.4.160

Abstract PDF PubReader ePub

Purpose

This study aimed to assess whether a young age at the time of diagnosis with osteosarcoma has value to predict the prognosis.

Materials and Methods

Sixty-seven children with stage II osteosarcoma were stratified according to the age of 10. There were 32 preadolescents (≤10 years) and 35 adolescents (10<age≤15 years). The patients were analyzed for their clinical characteristics, the histologic response to preoperative chemotherapy, event-free survival (EFS) and the patterns of relapse.

Results

After a median follow-up of 54 months (range: 6~153 months), the 5-year EFS of the preadolescent and adolescent groups was 64.5±9.3% and 58.2±9.1%, respectively, and age did not have any statistical significance for survival (p=0.55). Cox regression analysis revealed that both the serum level of alkaline phosphatase and the histologic response to preoperative chemotherapy were significantly related to survival of the 67 patients. Those patients aged less than 7 years responded poorly to preoperative chemotherapy and their rate of amputation was 43%. However, their 5-year EFS was not statistically different from the older patients (57.1±18.7 vs 67.7±6.3%, respectively, p=0.58).

Conclusions

We could not find any statistical difference in the clinical characteristics and survival from osteosarcoma for the preadolescents and adolescents, so the current approach of having the same protocol for both groups of patients seems to be reasonable.

Citations

Citations to this article as recorded by

Tumor necrosis drives prognosis in osteosarcoma: No difference in chemotherapy response and survival between chondroblastic and osteoblastic osteosarcoma
Neel Patel, Joseph O. Werenski, Marcos R. Gonzalez, Marilee J. Clunk, Meagan R. McCadden, Alexis Richard, Ivan Chebib, Yin P. Hung, G. Petur Nielsen, Santiago A. Lozano-Calderon
Surgical Oncology.2024; 57: 102155. CrossRef
Limb salvage surgery has a higher complication rate than amputation but is still beneficial for patients younger than 10 years old with osteosarcoma of an extremity
Yoichi Kaneuchi, Shinichirou Yoshida, Tomohiro Fujiwara, Scott Evans, Adesegun Abudu
Journal of Pediatric Surgery.2022; 57(11): 702. CrossRef
Molecular profiling of osteosarcoma in children and adolescents from different age groups using a next-generation sequencing panel
G.M. Guimarães, F. Tesser-Gamba, A.S. Petrilli, C.R.P. Donato-Macedo, M.T.S. Alves, F.T. de Lima, R.J. Garcia-Filho, R. Oliveira, S.R.C. Toledo
Cancer Genetics.2021; 258-259: 85. CrossRef
Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt
Ahmed M. Morsy, Badawy M. Ahmed, Khalid M. Rezk, Islam K.-A. Ramadan, Amir M. Aboelgheit, Hanan A. Eltyb, Osama M. Abd Elbadee, Maha S. El-Naggar
Journal of Pediatric Hematology/Oncology.2020; 42(2): e66. CrossRef
miR-202-5p inhibits the migration and invasion of osteosarcoma cells by targeting ROCK1
Congda Li, Deying Ma, Jinhu Yang, Xiangbo Lin, Bo Chen
Oncology Letters.2018;[Epub] CrossRef
Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults
Sabrina Jeane Prates Eleutério, Andreza Almeida Senerchia, Maria Teresa Almeida, Cecilia Maria Da Costa, Daniel Lustosa, Luiz Mario Calheiros, Jose Henrique Silva Barreto, Algemir Lunardi Brunetto, Carla Renata Pacheco Donato Macedo, Antonio Sergio Petril
Pediatric Blood & Cancer.2015; 62(7): 1209. CrossRef
Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data
Hai-Yong Ren, Ling-Ling Sun, Heng-Yuan Li, Zhao-Ming Ye
BioMed Research International.2015; 2015: 1. CrossRef
Identification of Osteosarcoma-Related Specific Proteins in Serum Samples Using Surface-Enhanced Laser Desorption/Ionization-Time-of-Flight Mass Spectrometry
Jianli Gu, Jitian Li, Manyu Huang, Zhiyong Zhang, Dongsheng Li, Guoying Song, Xingpo Ding, Wuyin Li
Journal of Immunology Research.2014; 2014: 1. CrossRef
Comparison between preadolescent and adolescent patients with high-grade osteosarcoma in China
Weixiang Qi, Zan Shen, Lina Tang, Aina He, Yumei Yang, Feng Lin, Yang Yao
The Chinese-German Journal of Clinical Oncology.2012; 11(5): 274. CrossRef
The relation of tumour necrosis and survival in patients with osteosarcoma
Xin Li, Adedayo O. Ashana, Vincent M. Moretti, Richard D. Lackman
International Orthopaedics.2011; 35(12): 1847. CrossRef
Osteosarcoma in children 5 years of age or younger at initial diagnosis
Jennifer Worch, Katherine K. Matthay, John Neuhaus, Robert Goldsby, Steven G. DuBois
Pediatric Blood & Cancer.2010; 55(2): 285. CrossRef

9,612 View
59 Download
11 Crossref

First
Prev
Page of 1
Next
Last

Search